Physician profile
Anna K Shaw
NPI 1265763676
$1,386.12
in general payments reported to CMS, 2019-2025
21 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2024: $325 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.80 | 2024-2025 | |
| Allergan, INC. | $192.61 | 2021 | |
| Medtronic, INC. | $151.45 | 2024 | Reveal Linq |
| Scpharmaceuticals INC. | $132.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $131.01 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $99.97 | 2025 | Dupixent |
| Amgen INC. | $64.29 | 2025 | Otezla, Otezla |
| Journey Medical Corporation | $42.01 | 2021 | |
| Genzyme Corporation | $40.34 | 2025 | |
| Lilly USA, LLC | $38.80 | 2025 | Taltz, Ebglyss |
| Merz North America, INC. | $38.33 | 2021 | |
| Ucb, INC. | $38.07 | 2025 | Bimzelx |
| Organogenesis INC. | $37.11 | 2024 | Matrix |
| Revance Therapeutics, INC. | $32.98 | 2025 | Daxxify |
| Botanix Sb INC | $25.89 | 2025 | Sofdra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $20.55 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $18.87 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.26 | 2025 | Ycanth |
| Galderma Laboratories, L.P. | $14.53 | 2025 | |
| Arcutis Biotherapeutics, INC. | $14.45 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.85 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.